Targeting cancer: the new frontier of immunotherapy and precision oncology
Published: Jan. 2023
New technologies for fighting cancer are extending some patients’ lives and hold the vast potential to do the same for many others — in some cases offering cures for diseases that were once considered a death sentence. Immunotherapies rely on biological targets that scientists can use to turn the immune system into a weapon that kills cancer cells or disables the malignant cells’ defenses.
This report is an authoritative guide to these game-changing treatments, informed by STAT’s original reporting and expert analysis. In it, you will:
- Get the latest information about these novel therapies and their successes and failures.
- Gain an understanding of the biology of cancer targets and the strategies scientists are using in designing drugs to harness them.
- And learn about five cancer targets — LAG-3, TGF-beta, CLDN6, mesothelin, and KRAS — that pharmaceutical and biotech companies are actively pursuing.